Jeremy Caldwell Ph.D Overview

  • Primary Position
  • Chief Executive...

  • Primary Industry
  • Healthcare

  • Active Board Seats
  • 2

  • Med. Deal Size

  • Med. Valuation

Jeremy Caldwell Ph.D General Information

Biography

Dr. Jeremy Caldwell served as Chief Executive Officer and President at Inception Sciences. He serves as a Board Member at BioGraph 55 and Sardona Therapeutics. He also served as a Venture Partner at Versant Ventures. He served as a Board Member at Belharra Therapeutics and Odyssey Thera. He served as Co-Chief Executive Officer and Board Member at Lycia Therapeutics. He served as a Board Member at Chinook Therapeutics. He serves as a Partner at Red Tree Venture Capital. A widely respected executive and scientist with deep industry expertise built through a decorated career in industry and venture activities, his accomplishments span from creating innovative drug development companies to driving the discovery, development, and translation of novel therapies. He has forged deep ties to the San Diego and San Francisco Bay Area biotechnology communities, as well as far-reaching relationships within the global pharmaceutical space. Most recently he was CEO of Inception Therapeutics, Versant Ventures' San Diego-based discovery engine for new company formation, a venture partner with Versant Ventures, and a member of the firm's investment team. In these roles, he co-led the formation of Chinook Therapeutics (acquired by Novartis for $3.5B), and co-led the investment and formation of Lycia Therapeutics, Belharra Therapeutics, Light Horse Therapeutics, among others, acting as founding CEO and board director of each. Before Inception/Versant, he was an entrepreneur-in-residence at Third Rock Ventures, where he participated in the genesis and formation of Revolution Medicines (RVMD), Pliant Therapeutics (PLRX), Decibel Therapeutics (DBTX), Relay Therapeutics (RLAY) and Nurix Therapeutics (NRIX). He also played key roles in the foundational science on which Rigel, Inc. (RIGL), and Kalypsys, Inc., were formed, as well as advising in the evolution of Syrrx, Inc. (acquired by Takeda for $270M). With drug discovery and development expertise primarily focused on oncology, immunology, neurology, and cardiometabolic disease, he is credited with significant contributions to research leading to four commercial drugs. He previously served as executive vice president and chief scientific officer at Ardelyx, Inc., where he advanced a portfolio of novel anti-fibrotic and cardiorenal therapeutics to the clinic. His career has also included key leadership roles with Sirna, Merck Research Laboratories, and the Genomics Institute of the Novartis Research Foundation (GNF). He is a member of the board of Sardona Therapeutics. He received a B.S. in molecular and cellular biology with an emphasis in neuroscience from the University of California at Berkeley and a Ph.D. in molecular pharmacology from Stanford University.

Contact Information

Primary Position
Chief Executive Officer & President, Inception Sciences
Education
Stanford University, Ph.D. (Doctor of Philosophy)
University of California, Berkeley, BS (Bachelor of Science)
Gender
Male
Email
jc
Phone
+1 (925)
Address
  • 4550 Norris Canyon Road
  • Suite 140
  • San Ramon, CA 94583
  • United States
+1 (925)

Jeremy Caldwell Ph.D Positions (1)

Firm name Firm type Title Location Industry Since
Red Tree Venture Capital Investor Partner Redwood City, CA Venture Capital

Jeremy Caldwell Ph.D Board Seats (3)

Company Industry Ownership Status Financing Status Location Since
BioGraph 55 Biotechnology Privately Held (backing) Venture Capital-Backed San Francisco, CA
Odyssey Thera Drug Discovery Out of Business Formerly VC-backed San Ramon, CA
Sardona Therapeutics Discovery Tools (Healthcare) Privately Held (backing) Venture Capital-Backed San Francisco, CA

Jeremy Caldwell Ph.D Lead Partner on Deals (3)

Jeremy Caldwell Ph.D has been the lead partner on 3 deals. Their latest deal was with BioGraph 55, a biotechnology company. The deal was made for on 01-Jun-2024.

Company Deal Date Deal Type Deal Size Deal Status Industry Location
BioGraph 55 01-Jun-2024 Later Stage VC (Series A1) Completed Biotechnology San Francisco, CA
Lycia Therapeutics 09-Sep-2021 Completed Drug Discovery South San Francisco, CA
Chinook Therapeutics 22-Aug-2019 Completed Drug Discovery Seattle, WA

Jeremy Caldwell Ph.D Network (73)

Board Members (35)

Name Company Representing Location From
William Greenman Chinook Therapeutics Self Seattle, WA
Robert Azelby Chinook Therapeutics Self Seattle, WA
Belharra Therapeutics Belharra Therapeutics San Diego, CA
Lycia Therapeutics Cowen Healthcare Investments South San Francisco, CA
Chinook Therapeutics Self Seattle, WA

Portfolio Executives (18)

Name Company Role Deal date Location
Paul Tumeh MD BioGraph 55 Founder, Chief Executive Officer & Board Member 01-Jun-2024 San Francisco, CA
Alexander Johnson BioGraph 55 Chief Operating Officer 01-Jun-2024 San Francisco, CA
BioGraph 55 Executive 01-Jun-2024 San Francisco, CA
Lycia Therapeutics Vice President of Finance 09-Sep-2021 South San Francisco, CA
Lycia Therapeutics Chief Business Officer 09-Sep-2021 South San Francisco, CA

Fund Team Members (20)

Name Investor Fund Fund Location
Samad Wahid MD Red Tree Venture Capital Red Tree Venture Fund II Redwood City, CA
Samad Wahid MD Red Tree Venture Capital Red Tree Venture Fund Redwood City, CA
Red Tree Venture Capital Redwood City, CA
Red Tree Venture Capital Redwood City, CA
Versant Ventures San Francisco, CA

Jeremy Caldwell Ph.D Affiliated Funds (4)

Fund Investor Fund Type Status Vintage Size Dry Powder IRR IRR Quartile
Red Tree Venture Fund II Red Tree Venture Capital Venture Capital - Early Stage Open 2024
Red Tree Venture Fund Red Tree Venture Capital Venture Capital - Early Stage Closed 2022
Versant Voyageurs I Versant Ventures Venture - General Closed 2018
Versant Venture Capital VI Versant Ventures Venture Capital - Early Stage Fully Invested 2017

Jeremy Caldwell Ph.D FAQs

  • Who is Jeremy Caldwell Ph.D?

    Dr. Jeremy Caldwell served as Chief Executive Officer and President at Inception Sciences.

  • How much does Jeremy Caldwell Ph.D typically invest?

    Jeremy Caldwell Ph.D's median deal size is .

  • What is Jeremy Caldwell Ph.D’s main position?

    Jeremy Caldwell Ph.D’s primary position is Chief Executive Officer & President.

  • What are the contact details for Jeremy Caldwell Ph.D?

    Jeremy Caldwell Ph.D’s email address is jc and his phone number is +1 (925) .

  • How many active board seats does Jeremy Caldwell Ph.D hold?

    Jeremy Caldwell Ph.D holds 3 board seats including BioGraph 55, Odyssey Thera, and Sardona Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »